Alkermes (ALKS) Return on Capital Employed (2011 - 2026)
Alkermes (ALKS) reported Return on Capital Employed of 6.92% for Q1 2026, down 1715.0% year-over-year from 0.43% in Q1 2025, and down 49.19% quarter-over-quarter from 13.62% in Q4 2025.
Alkermes (ALKS) Return on Capital Employed (2011 - 2026) Analysis & Trends
Alkermes (ALKS) has 16 years of Return on Capital Employed data on file, last reported at 6.92% in Q1 2026.
- Return on Capital Employed for Q1 2026 came in at 6.92%, down 1715.0% year-over-year; the trailing twelve-month figure through Mar 2026 was 6.92% (down 1715.0% YoY), and the FY2025 annual result was 14.7%, down 1110.0% from the prior year.
- Return on Capital Employed declined to 6.92% in Q1 2026 per ALKS's latest filing, from 13.62% in the prior quarter.
- Over five years, Return on Capital Employed peaked at 27.46% in Q3 2023 and troughed at 3.9% in Q2 2024.
- A 5-year average of 10.19% and a median of 6.4% in 2024 frame the typical range for Return on Capital Employed.
- The sharpest annual moves came in 2023 and 2024: Return on Capital Employed jumped 2694 bps in 2023, then slumped 3029 bps in 2024.
- A 5-year view of Return on Capital Employed shows it stood at 0.42% in 2022, then surged by 846 bps to 3.12% in 2023, then jumped by 721 bps to 25.64% in 2024, then plunged by 47 bps to 13.62% in 2025, then tumbled by 49 bps to 6.92% in 2026.
- Business Quant data shows ALKS's Return on Capital Employed at 6.92% in Q1 2026, 13.62% in Q4 2025, and 19.73% in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 8.52% |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 27.58% |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 21.43% |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | - |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 20.04% |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 7.34% |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | 6.92% |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 14.85% |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -1.92% |
| 10 | Liquidia | 5.63 Bn | 5.40 Bn | 121.79 Mn | 21.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 6.92% |
| Dec 31, 2025 | 13.62% |
| Sep 30, 2025 | 19.73% |
| Jun 30, 2025 | 22.52% |
| Mar 31, 2025 | 24.07% |
| Dec 31, 2024 | 25.64% |
| Sep 30, 2024 | -2.83% |
| Jun 30, 2024 | -3.90% |
| Mar 31, 2024 | 6.40% |
| Dec 31, 2023 | 3.12% |
| Sep 30, 2023 | 27.46% |
| Jun 30, 2023 | 20.75% |
| Mar 31, 2023 | 0.66% |
| Dec 31, 2022 | -0.42% |
| Sep 30, 2022 | 0.52% |
| Jun 30, 2022 | 3.19% |
| Mar 31, 2022 | 5.69% |
| Dec 31, 2021 | 6.35% |
| Sep 30, 2021 | -4.12% |
| Jun 30, 2021 | -3.50% |